The Estonian company Selfdiagnostics brings laboratory-grade precision home medical testing to ordinary users and offers the world’s smallest application of PCR technology. This unique product paves the way for bigger changes in medicine in regard to patients taking the first steps toward diagnosing illnesses.
“Health care issues are a salient topic, and services in the field are certainly not as available to people as they would like. People are also used to making increasingly more decisions about their health themselves, and they are quite well-informed. Today people tend to try to take the initiative themselves as the first step toward understanding what the problem is and how it might be treated,” says CEO and co-founder Marko Lehes.
Selfdiagnostivs OÜ is a research and development company founded in 2008, its goal is to develop and market services and products necessary to prevent or control health care issues.
Read Marko Lehes interview on Connected Health website.
Applied research in smart specialisation growth areas (NUTIKAS) support aims to contribute to growth in the research-intensity of the Estonian economy, supporting collaboration between R&D institutions and companies. Furthermore, the support will help to raise the capabilities of R&D institutions to carry out applied research needed for business in smart specialisation growth areas.
The funding is intended for a company registered in the Estonian commercial register, for the benefit of which a study or product development project in the smart specialisation growth area will be carried out by a research institution.
NUTIKAS measure is funded by European Regional Development Fund
Grant recipient: Selfdiagnostics OÜ
Researcher: UT Institute of Technology
Grant sum: 1 616 013 €